Recent Updates
Recently added Catalysts
BMRN Neutral Sentiment

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a...

Key Takeaway: BioMarin Pharmaceutical Inc. has announced a conference call and webcast set for August 4, 2025, at 4:30 p.m. ET, where CEO Alexander Hardy will discuss the company's financial results for the second quarter of 2025. The live audio webcast will be accessible through BioMarin's investor website, and a replay will be available for one week post-call. BioMarin continues to position itself as a leader in developing treatments for genetic conditions, emphasized by its robust pipeline and history of innovation.
Price reaction · baseline $56.56 (2025-07-21 close) · hit after-hours · 1 other BMRN headline(s) in the window, move may be shared
day 0 close · peak
+4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • BioMarin is hosting a conference call to discuss its financial results, indicating transparency and engagement with stakeholders.
  • The company has a proven track record with eight commercial therapies, highlighting its innovative capabilities.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
7.9%
average across 8 past catalysts
Lead asset
Valoctocogene roxaparvovec
Phase 3 · Hemophilia A

Full Press Release Details

SAN RAFAEL, Calif. , July 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 4, 2025 , at 4:30 p.m. ET to discuss second quarter 2025 financial results and provide a general business update.
Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871 International Dial-in Number: 646-307-1963 Conference Call ID: 6336054
U.S. / Canada Replay Dial-in Number: 800-770-2030 International Replay Dial-in Number: 609-800-9909 Playback ID: 6336054
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/ . A replay of the call will be archived on the site for one week following the call.
About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California -based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com .
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803

Frequently Asked Questions

When is BioMarin's conference call scheduled?

The conference call is on August 4, 2025, at 4:30 p.m. ET.

How can I access BioMarin's conference call?

You can access it via the investor section of BioMarin's website.

What is BioMarin's focus as a biotechnology company?

BioMarin focuses on developing medicines for rare genetic conditions.

What is the purpose of the conference call?

The call will discuss second quarter 2025 financial results and business updates.

How can I replay the BioMarin conference call?

A replay will be available on the website for one week after the call.

Last updated: Jul 22, 2025